Abstract 1771
Background
Platelet activation and the release of various growth factors from platelet granules in response to tumor cell profoundly influence tumor biology. Platelet hyperreactivity in cancer patients is a frequently discussed phenomenon; however, cancer patients were also found to have platelet dysfunction. Considerably less is known about exhaustion of platelet kinetics in cancer.
Methods
In this study, we investigated kinetics of intra-platelet growth factors in hepatocellular carcinoma (HCC) recurrence. We prospectively recruited forty patients diagnosed with HCC who were undergoing liver resection. The patients were followed every three months with imagings after the resection. Platelet fractions were separately isolated before and after a month of radical resection of the tumor. Growth factors/cytokines were measured using enzyme-linked immunosorbent assay (ELISA) kits. Follow-up was standardized to two years. HCC recurrence was diagnosed on the basis of imaging.
Results
Fifteen patients developed post-resection HCC recurrence during 2-year follow-up. The concentrations of platelet-alpha granules secreted growth factors [vascular endothelial growth factor-A (VEGF-A), angiopoietin-1(Ang-1)] and dense granules secreted growth factors (serotonin) were significantly depleted in patients with early HCC recurrence. In addition, the post-resection platelet count was also significantly lower in patients with recurrence than those without recurrence. A combined receiver-operating characteristic (ROC) curve generated to determine the cut-off values for these growth factors yielded both specificity and sensitivity of greater than 80%, area under curve (AUC) > 0.8, and P < 0.001. Furthermore, in the binary logistic regression model, VEGF-A was able to independently predict early HCC recurrence (P < 0.05); accordingly, the disease-free interval was substantially worse in accordance with the exhausted intra-platelet growth factors.
Conclusions
We found a qualitative and quantitative platelet crisis, and its prognostic implication in patients with post-resection HCC recurrence. This study provides an avenue to identify the pathophysiological mechanism of the impaired platelet-kinetics and its relevance in cancer biology.
Clinical trial identification
Legal entity responsible for the study
Bibek Aryal.
Funding
Japan Society for the Promotion of Science (JSPS).
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3458 - Circulating tumour DNA (ctDNA) as a tool to assess response and guide therapy adaptation in rectal cancer
Presenter: Shelize Khakoo
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3744 - A Genetic Analysis of Gemcitabine-Induced High-Grade Neutropenia in Pancreatic Cancer Patients
Presenter: Federico Innocenti
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3986 - Effect of a combined treatment with iPS cells derived dendritic cells and proton beam irradiation in a murine subcutaneous melanoma model
Presenter: Yuzi Wang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2042 - Developing the liquid biopsy in gastroesophageal adenocarcinoma: Disease monitoring and detection of minimal residual disease
Presenter: Mark Openshaw
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
665 - Survival from breast cancer in patients with BRCA1/2, CHEK2, NOD2 mutations and TP53 (c.[215G>C]) polymorphisms.
Presenter: Joanna Huszno
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1648 - Phase I pharmacological study of continuous chronomodulated capecitabine treatment
Presenter: Jeroen Roosendaal
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3714 - Head and Neck (HN) Primary Sarcomatoid Carcinoma (PSC) profile by High-throughput somatic mutation profiling.
Presenter: Vincent Fallet
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5048 - A composite liquid biomarker for non-invasive diagnosis of resectable pancreatic ductal adenocarcinoma
Presenter: Andreas Berger
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5071 - Acquired chemoresistance of colorectal cancer (CRC) cells is accompanied by pro-invasive VEGF-signaling that can be attenuated by aflibercept
Presenter: Annette LARSEN
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5278 - Actionable Mutations and Overall Survival in 3,211 Patients with Cancer: The Hellenic Cooperative Oncology Group Precision Medicine Initiative
Presenter: Elena Fountzila
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract